What is the long-term trend for Phathom Pharmaceuticals, Inc.'s stock issuance proceeds?

Over 3 years (2021 to 2025), Phathom Pharmaceuticals, Inc.'s stock issuance proceeds has grown at a -5.5% compound annual growth rate (CAGR), from $1.94M to $1.64M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Phathom Pharmaceuticals, Inc. PHAT Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Zevra Therapeutics, Inc.ZVRA

$752K—

Theravance BiopharmaTBPH

$241K+1,105%

HRO

HarrowHROW

$25K+8.7%

PrecigenPGEN

$0+100%

Agios PharmaceuticalsAGIO

$2.08M+28.4%

Mirum Pharmaceuticals, Inc.MIRM

$10.13M+59.3%

Other financials

Income statement

See full

Revenue$58.3M+104%

Gross profit$46.3M+86.8%

Operating income-$15.5M+80.4%

Net income-$30.4M+67.8%

EPS (diluted)-$0.37+71.8%

Balance sheet

See full

Cash & equivalents$180.9M-14.8%

Total debt$166.3M-18.3%

Total equity-$337.0M+0.4%

Total assets$305.1M+3.7%

Cash flow

See full

Operating cash flow-$15.6M+81.6%

CapEx$61.0K+239%

Free cash flow-$15.7M+81.5%

Valuation

See full

Market cap$824.68M+13.4%

Enterprise value$810.08M+12.7%

P/S4×-4.9×

Profitability

See full

Gross margin84.9%-1.3pp

Operating margin-47.1%-21.9pp

Net margin-76.8%-34.5pp

FCF margin-47.7%-22.1pp

Returns & leverage

See full

Return on equity-147.9%—

Debt / equity5.6×—

Current ratio2.2×-1.4×

Where this comes from

Reported directly by Phathom Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Phathom Pharmaceuticals, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Phathom Pharmaceuticals, Inc.'s stock issuance proceeds?: Phathom Pharmaceuticals, Inc. (PHAT) reported stock issuance proceeds of $591K in Q1 2026.
What is the long-term trend for Phathom Pharmaceuticals, Inc.'s stock issuance proceeds?: Over 3 years (2021 to 2025), Phathom Pharmaceuticals, Inc.'s stock issuance proceeds has grown at a -5.5% compound annual growth rate (CAGR), from $1.94M to $1.64M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.